Paper Details

  1. Home
  2. Paper Details

Effectiveness of eletriptan in reducing time loss caused by migraine attacks.

Author: SteinerT J, WellsN E

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study found that eletriptan significantly reduced the amount of time lost from usual activities during a migraine attack compared to placebo.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The growing literature on the economics of migraine and its treatment generally indicates that the direct healthcare costs of managing the disorder are relatively low compared with the personal and societal burdens resulting from the disruption to normal functioning caused by migraine at...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2165/00019053-200018060-00003

データ提供：米国国立医学図書館（NLM）

Eletriptan: A New Weapon Against Migraine?

Migraines can wreak havoc on daily life, leading to significant time loss and decreased productivity. Researchers are constantly seeking new and effective treatments to alleviate migraine symptoms and minimize their disruptive impact. This study investigates the effectiveness of eletriptan, a new selective serotonin (5-HT)5-HTIB/ID agonist, in reducing time loss associated with migraine attacks.

The study compared eletriptan at two different doses (40 mg and 80 mg) to placebo in a randomized clinical trial. The researchers found that both doses of eletriptan significantly reduced the amount of time patients were unable to perform their usual activities during a migraine attack. The study highlights the potential of eletriptan to improve patient functioning and reduce the societal burden associated with migraine.

This study provides valuable evidence supporting the effectiveness of eletriptan in reducing the time loss associated with migraine attacks. It offers a glimmer of hope for migraine sufferers seeking to regain control of their lives and minimize the debilitating impact of these debilitating headaches.

Finding Relief and Regaining Control

This study is like a camel caravan traversing a desert of migraine pain, seeking a path to relief and control. The researchers, armed with their knowledge and skills, unearth a new weapon against migraine, offering hope for sufferers seeking to reclaim their lives.

A Step Towards Enhanced Migraine Management

This research highlights the importance of developing effective treatments that not only alleviate migraine symptoms but also minimize the associated time loss and functional impairment. The study's findings underscore the potential of eletriptan to improve patient quality of life and reduce the overall societal impact of migraine.

Dr.Camel's Conclusion

The research on eletriptan is like a camel caravan traversing a vast desert of migraine pain, seeking a path to relief and control. The researchers, armed with their knowledge and skills, unearth a new weapon against migraine, offering hope for sufferers seeking to reclaim their lives.

Date :
  1. Date Completed 2001-03-29
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

11227394

DOI: Digital Object Identifier

10.2165/00019053-200018060-00003

Related Literature

Article Analysis
・Effective treatment of migraine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.